VYNE
$1.16
Vyne Therapeutics
$.05
4.50%
VYNE
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.33)
Revenue:  $4.67 Mil
Thursday
Nov 11
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when VYNE reports earnings?
Beat
Meet
Miss

Where is VYNE's stock price going from here?
Up
Flat
Down
Stock chart of VYNE
Analysts
Summary of analysts' recommendations for VYNE
Score
Grade
Pivots
Resistance
$1.29
$1.25
$1.20

$1.16

Support
$1.11
$1.07
$1.02
Tweet
Growth
Description
VYNE Therapeutics Inc. focuses on developing and commercializing therapeutics for dermatology. The company's product pipeline consist FMX103 and FCD105 which are in clinical stage. VYNE Therapeutics Inc., formerly known as Menlo Therapeutics Inc., is based in Bridgewater, New Jersey.